Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
DrugDrug NameDrug Indication
DB00004Denileukin diftitoxFor treatment of cutaneous T-cell lymphoma
DB00008Peginterferon alfa-2aPeginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].
DB00011Interferon alfa-n1For treatment of venereal or genital warts caused by the Human Papiloma Virus
DB00012Darbepoetin alfaFor the treatment of anemia (from renal transplants or certain HIV treatment)
DB00016ErythropoietinIndicated in adult and paediatric patients for the: - treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. - treatment of anemia due to zidovudine in patients with HIV-infection. - treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. - reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
DB00018Interferon alfa-n3For the intralesional treatment of refractory or recurring external condylomata acuminata.
DB00019PegfilgrastimPegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. It is also indicated to increase in patients with acute myelosuppresive radiation exposure.
DB00020SargramostimFor the treatment of cancer and bone marrow transplant
DB00022Peginterferon alfa-2bPeginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
DB00026AnakinraFor the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
DB00033Interferon gamma-1bInterferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.
DB00034Interferon Alfa-2a, RecombinantFor the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
DB00038OprelvekinIndicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.[Label]
DB00041AldesleukinFor treatment of adults with metastatic renal cell carcinoma.
DB00060Interferon beta-1aFor treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
DB00068Interferon beta-1bInterferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
DB00069Interferon alfacon-1For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
DB00105Interferon alfa-2bFor the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
DB05258Interferon alfaInvestigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma.
DB05305Cintredekin BesudotoxInvestigated for use/treatment in brain cancer.
DB05332RomiplostimTreatment of chronic immune thrombocytopenic purpura.
DB05396Albinterferon Alfa-2BInvestigated for use/treatment in hepatitis (viral, C).
DB05718Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
DB05934CTCE-0214Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases.
DB06534ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
DB06562EmfilerminInvestigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility.
DB09103AncestimAncestim, in combination with filgrastim, is indicated for the setting of autologous peripheral blood progenitor cell transplantation in patients at risk of poor peripheral blood progenitor cell mobilisation.[L1090] The use of ancestim with filgrastim will generate a sustained increase in the number of peripheral blood progenitor cells capable of engraftment. It is used for mobilization of progenitor cells from the bone marrow to the peripheral blood with or withouth mobilizing chemotherapy. The harvested progenitor cells can be used for transplant following myelosuppressive or myeloablative therapies.[L1089]
DB09107Methoxy polyethylene glycol-epoetin betaFor the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
DB09122Peginterferon beta-1aFor the treatment of patients with relapsing forms of multiple sclerosis.
DB11624Epoetin deltaNot Available
DB11955AvoterminNot Available
DB11997Interleukin-7Not Available
DB12075NagrestipenNot Available
DB12182BinetrakinNot Available
DB12349DulanerminNot Available
DB12431MuplestimNot Available
DB12525MolgramostimNot Available
DB12699BalugrastimNot Available
DB12880Interleukin-10Not Available
DB13144LenograstimThe drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy. Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion. GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome).
DB13200LipegfilgrastimIndicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441].
DB14076Interleukin-1 alpha, human recombinantNot Available
DB05386RegramostimInvestigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
DB14767Peginterferon lambda-1aNot Available
DB14865Human interleukin-2Not Available
DB14999Human interferon betaNot Available
DB15015Recombinant CD40-ligandNot Available
DB15095LeridistimNot Available
DB15131Interferon alfa-2cNot Available
DB15386ALT-801Not Available
DB15389TeceleukinNot Available
DB15402Tucotuzumab celmoleukinNot Available
DB15443Lorukafusp alfaNot Available
DrugDrug NameTargetType
DB00004Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
DB00004Denileukin diftitoxCytokine receptor common subunit gammatarget
DB00004Denileukin diftitoxInterleukin-2 receptor subunit betatarget
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 2target
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 1target
DB00008Peginterferon alfa-2aCytochrome P450 1A2enzyme
DB00011Interferon alfa-n1Interferon alpha/beta receptor 2target
DB00011Interferon alfa-n1Interferon alpha/beta receptor 1target
DB00012Darbepoetin alfaErythropoietin receptortarget
DB00016ErythropoietinErythropoietin receptortarget
DB00018Interferon alfa-n3Interferon alpha/beta receptor 1target
DB00018Interferon alfa-n3Interferon alpha/beta receptor 2target
DB00019PegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB00019PegfilgrastimNeutrophil elastasetarget
DB00020SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB00020SargramostimBone marrow proteoglycantarget
DB00020SargramostimInterleukin-3 receptor subunit alphatarget
DB00020SargramostimCytokine receptor common subunit betatarget
DB00020SargramostimSyndecan-2target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 1target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 2target
DB00022Peginterferon alfa-2bCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2D6enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2C9enzyme
DB00026AnakinraInterleukin-1 receptor type 1target
DB00033Interferon gamma-1bInterferon gamma receptor 1target
DB00033Interferon gamma-1bInterferon gamma receptor 2target
DB00034Interferon Alfa-2a, RecombinantInterferon alpha/beta receptor 1target
DB00034Interferon Alfa-2a, RecombinantInterferon alpha/beta receptor 2target
DB00038OprelvekinInterleukin-11 receptor subunit alphatarget
DB00041AldesleukinInterleukin-2 receptor subunit betatarget
DB00041AldesleukinInterleukin-2 receptor subunit alphatarget
DB00041AldesleukinCytokine receptor common subunit gammatarget
DB00041AldesleukinProstaglandin G/H synthase 2enzyme
DB00041AldesleukinCytosolic phospholipase A2enzyme
DB00041AldesleukinCytochrome P450 3A4enzyme
DB00041AldesleukinXanthine dehydrogenase/oxidaseenzyme
DB00041AldesleukinCytochrome P450 2E1enzyme
DB00060Interferon beta-1aInterferon alpha/beta receptor 1target
DB00060Interferon beta-1aInterferon alpha/beta receptor 2target
DB00068Interferon beta-1bInterferon alpha/beta receptor 1target
DB00068Interferon beta-1bInterferon alpha/beta receptor 2target
DB00069Interferon alfacon-1Interferon alpha/beta receptor 1target
DB00069Interferon alfacon-1Interferon alpha/beta receptor 2target
DB00105Interferon alfa-2bInterferon alpha/beta receptor 2target
DB00105Interferon alfa-2bInterferon alpha/beta receptor 1target
DB00105Interferon alfa-2bCytochrome P450 1A2enzyme
DB05258Interferon alfaInterferon alpha/beta receptor 1target
DB05305Cintredekin BesudotoxInterleukin-13target
DB05332RomiplostimThrombopoietin receptortarget
DB05934CTCE-0214Stromal cell-derived factor 1target
DB06534ThrombopoietinThrombopoietin receptortarget
DB09103AncestimMast/stem cell growth factor receptor Kittarget
DB09107Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
DB13144LenograstimGranulocyte colony-stimulating factor receptortarget
DB13200LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB05386RegramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB05386RegramostimGM-CSF receptor alpha subunittarget
DB05386RegramostimCholinesteraseenzyme